Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNMF63
|
|||
| Drug Name |
YH003
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Biocytogen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05017623) A Multicenter, Open-label, Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH003 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Biocytogen | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.